Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Erectile Dysfunction
Effectiveness and Safety of Intracavernosal Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Erectile Dysfunction
Sponsor: Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
Listed as NCT02472431, this PHASE1/PHASE2 trial focuses on Erectile Dysfunction and Impotence, Vasculogenic and remains completed. Sponsored by Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation, it has been updated 7 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
▶ Show 2 earlier versions
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Oct 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation
- I.M. Sechenov First Moscow State Medical University
For direct contact, visit the study record on ClinicalTrials.gov .